Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lung disease
Biotech
PureTech creates Celea to develop promising lung disease drug
Using its hub-and-spoke model, PureTech is launching a new subsidiary, Celea Therapeutics, to develop its candidate for the rare lung disease IPF.
Kevin Dunleavy
Aug 12, 2025 10:46am
Expedition inks $645M Fosun deal to bring China asset to US
Aug 11, 2025 11:06am
AIRNA preps for clinical test with $155M series B
Apr 1, 2025 7:00am
Boehringer widens fibrosis drug's potential after 2nd ph. 3 win
Feb 10, 2025 10:42am
Roivant’s midstage asset fails to show benefit in lung disease
Dec 3, 2024 10:32am
After phase 2 data, Insilico plots pivotal lung disease trial
Nov 12, 2024 1:34pm
